VT-1161: Interim Phase IIa data

Interim data from a double-blind, U.S. Phase IIa trial in patients with moderate to severe interdigital tinea pedis who received at least 1 dose of treatment showed that once-daily oral VT-1161 for 14 days led to an effective therapeutic cure, defined as both effective clinical cure and mycologic cure at the test-of-cure (TOC) visit on day 42, in 42% of patients in both the low- and mid-dose arms vs. 0% for placebo (p<0.05 for both). Effective therapeutic cure was based on an improvement in 6 clinical signs and symptoms, while mycologic cure was defined as a negative fungal culture. Viamet said the trial was not powered for statistical significance. VT-1161 was well tolerated with no serious adverse events reported. ...